Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
中国医学科学院血液病医院(血液学研究所)
Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Neuroblastoma神经母细胞瘤1 paper led
- Multiple myeloma多发性骨髓瘤47 papers led28 open trials led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病13 papers led12 open trials led
- Aplastic anaemia再生障碍性贫血48 papers led9 open trials led
- Beta thalassaemiaβ 地中海贫血1 paper led
- Haemophilia A血友病 A25 papers led5 open trials led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
- Fanconi anaemia范可尼贫血3 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- Gaucher disease戈谢病0 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Ewing sarcoma, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, IgA nephropathy, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Tianjin for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 47 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 2.8%.
5 hospitals in Tianjin for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 52
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingIASO206 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07322159
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingMRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07409454
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07585760
Age 18 years to 80 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07652905
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingBCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06793449
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06793475
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingBCMA CAR-T for Dynamic High-risk Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06880393
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of CT0596 in Plasma Cell Leukemia
- Phase
- Early phase 1
- Started
- 2025-06
- Registry
- NCT06988059
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106671
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106684
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106710
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingMRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106736
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAutologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT07109323
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingClinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT07169500
Age 18 years to 50 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-03
- Registry
- NCT07249073
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingBCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06745687
Age 18 years to 78 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2023-08
- Registry
- NCT05979363
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingDVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06158269
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
- Phase
- Phase 1/Phase 2
- Started
- 2022-07
- Registry
- NCT05632380
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingNational Longitudinal Cohort of Hematological Diseases
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04645199
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07399444
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou
- Not yet recruitingA Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07539233
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingSonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
- Phase
- Phase 1/Phase 2
- Started
- 2026-08
- Registry
- NCT07687004
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07726160
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingHP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07811986
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingCM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07830485
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingQLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- Phase
- Phase 2
- Started
- 2026-12
- Registry
- NCT07903636
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Phase
- Phase 1
- Started
- 2026-02
- Registry
- NCT07409246
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin
- RecruitingA Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07452198
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an
- RecruitingStudy to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07529782
Age Not stated to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin
- RecruitingCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07555938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07579234
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingSafety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07620275
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingGR1803 Injection in Patients With RRMM
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06952075
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingPhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07018050
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingLCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07100067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan
- RecruitingA Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07312188
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
- Phase
- Phase 1/Phase 2
- Started
- 2024-02
- Registry
- NCT06232096
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingStudy of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-05
- Registry
- NCT06375044
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingLong-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07028970
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou
- RecruitingPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Phase
- Phase 3
- Started
- 2022-09
- Registry
- NCT05243797
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2022-11
- Registry
- NCT05521802
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05623020
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2021-02
- Registry
- NCT04634552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Phase
- Phase 3
- Started
- 2021-10
- Registry
- NCT05020236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- Not yet recruitingStudy of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07910903
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingStudy of CM336 in Relapsed or Refractory Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT07181239
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingA Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-08
- Registry
- NCT06500507
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led47
- Harnessing Targeted Photodynamic Therapy to Synergistically Activate T Cell and NK Cell Responses in Multiple Myeloma.
- Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
- Prodigiosin inhibits proliferation and induces apoptosis through influencing amino acid metabolism in multiple myeloma.
- Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma.
- Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma.
- Identification and transformation of novel targets for immunotherapy in multiple myeloma.
- Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing.
- Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation.
- Raman spectroscopy of dried serum for the detection of rapid noninvasive multiple myeloma.
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
- T(11;14) with multiple myeloma: Standard risk survival but slow and poor response.
- Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).
- Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
- Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
- Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
- Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing.
- Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
- CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.
- B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.
- DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.
- LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.
- Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
- Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.
- Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.
- Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.
- Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma.
- Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.
- Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase.
- Immunotherapy for multiple myeloma: new chances and hope.
- Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
- CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression.
- Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
- Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
- Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma.
- Multiple myeloma-derived miR-27b-3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment.
- Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
- The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.
- The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma.
- Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma.
- Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
- Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.
- Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
- Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma.
- Comparative analysis of three serum-free light-chain detection systems in the diagnosis of multiple myeloma.
- A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.
- The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
- Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance.
Chinese-language papers (not in the count)17
- [Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].
- [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].
- [Clinical analysis of 14 patients aged ≤ 50 years with high-risk multiple myeloma treated with allogeneic hematopoietic stem cell transplantation].
- [Establishment of Patient-Derived Xenograft (PDX) Zebrafish Model of Multiple Myeloma and Its Application in Drug Screening].
- [Safety and feasibility of 120 min rapid infusion regimen of daratumumab in patients with multiple myeloma].
- [Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma].
- [The Clinical Significance of Oligoclonal Bands in Patient with Multiple Myeloma].
- [Clinical characteristics and prognosis of 46 patients with macrofocal multiple myeloma].
- [Diagnostic and prognostic value of serum miR-19a-3p in patients with multiple myeloma].
- [Establishment and comparison of three human multiple myeloma cell line transplantation models in mice].
- [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
- [Cdc37 Expression in Multiple Myeloma and Its Role in Cell Proliferation].
- [Two Serum Free Light Chain Detection Systems in the Diagnosis of Multiple Myeloma].
- [Clinical Analysis of Patients with MGUS, Primary Light Chain Amyloidosis, Multiple Myeloma or Multiple Myeloma with Concurrent Amyloidosis].
- [Immunoglobulin M multiple myeloma: a six-case report and literature review].
- [Progress in clonal evolution of multiple myeloma].
All its trials on ClinicalTrials.gov, any status92
- A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
- CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
- MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
- QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
- HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
- ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
- CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
- Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
- A Study of CT0596 in Plasma Cell Leukemia
- MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
- ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
- BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
- Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
- Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
- A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
- BCMA CAR-T for Dynamic High-risk Multiple Myeloma
- BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
- DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
- National Longitudinal Cohort of Hematological Diseases
- A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
- YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
- Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
- A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
- A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
- BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
- CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma
- ctDNA Methylation Sequencing for Myeloma
- Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
- Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
- a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
- Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
- Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
- LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
- Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
- A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- GR1803 Injection in Patients With RRMM
- A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
- A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
- A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
- Study of 3D189 in Patients With Hematologic Malignancies
- BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
- A Study of Daratumumab
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- A Study of TQB3820 in Patients With Hematological Malignancies
- A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
- Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 13 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 5.8%.
3 hospitals in Tianjin for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 20
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Registry
- NCT06764238
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingNewly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06882057
Age 1 year to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingCD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07106749
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingNewly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT07152041
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan
- RecruitingCD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06355739
Age 3 years to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06387121
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEfficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06481228
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEfficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06481241
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCombination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06608732
Age 16 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingEvaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07539610
Age 18 years to 69 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingImmunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07840976
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07234045
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingPhase I Study of FXS0683 in the Treatment of Blood Tumors
- Phase
- Phase 1
- Started
- 2026-06
- Registry
- NCT07616089
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingTCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Registry
- NCT06481735
Age 16 years to 70 years (registered criteria)
Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin
- RecruitingA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- Phase
- Early phase 1
- Started
- 2025-09
- Registry
- NCT07205315
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06179524
Age Not stated to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingInaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06450067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05667506
Age 3 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou
- RecruitingA Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT05334823
Age 3 years to 21 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
- RecruitingA Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Phase
- Phase 1/Phase 2
- Started
- 2022-11
- Registry
- NCT05579132
Age 2 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led13
- Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.
- Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report.
- Comprehensive omics-based classification system in adult patients with B-cell acute lymphoblastic leukemia.
- Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission.
- Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.
- Effectiveness and safety of blinatumomab for pediatric B cell acute lymphoblastic leukemia with Loeffler's endocarditis.
- Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia.
- Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.
- Functional diversification and dynamics of CAR-T cells in patients with B-ALL.
- Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report.
- Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
- A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.
- Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.
Chinese-language papers (not in the count)4
- [How I manage relapsed/refractory B-cell acute lymphoblastic leukemia patients treated with CD19 CAR- T cells throughout whole-process management].
- [The safety and efficacy of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia in children].
- [Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia].
- [Optimized treatment of childhood B-lineage acute lymphoblastic leukemia].
All its trials on ClinicalTrials.gov, any status29
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
- Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
- Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
- Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
- Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
- A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia
- γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
- CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
- CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
- CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
- Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
- Phase I Study of FXS0683 in the Treatment of Blood Tumors
- A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
- CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 48 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 11.7%.
2 hospitals in Tianjin for aplastic anaemia63 hospitals in China for aplastic anaemia
Open trials with this hospital 10
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAdverse Effects of ATG/ALG Therapy in Aplastic Anemia
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07461116
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingPhase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT07714512
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingReproductive and Mental Health of Patients With Aplastic Anemia
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06936930
Age 18 years to 40 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingDose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT07010237
Age 65 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingThe Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Registry
- NCT07287228
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingBrain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07578675
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingRituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
- Phase
- Phase 2
- Started
- 2023-02
- Registry
- NCT06254560
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingNational Longitudinal Cohort of Hematological Diseases
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04645199
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingEfficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07078721
Age 18 years to 50 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingStudy of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT06791824
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led48
- Somatic mutations and the efficacy of immunosuppressive therapy in severe/very severe aplastic anemia and transfusion-dependent nonsevere aplastic anemia.
- Assessing serum thrombopoietin for enhanced diagnosis of ITP, AA, and MDS using machine learning: A retrospective cohort study.
- The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia.
- Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.
- Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia.
- Comparison of Hetrombopag and Eltrombopag Added to First-Line Immunosuppressive Therapy in Severe Aplastic Anemia.
- Platelet transfusion refractoriness within one month post-hematopoietic stem cell transplantation does not impair survival in aplastic anemia patients after engraftment: a propensity score-matched analysis.
- Cost utility analysis of adult patients with severe aplastic anemia: a single-center study.
- Application of platelet transcriptomics for assessing treatment effectiveness and predicting long-term platelet counts recovery in aplastic anemia.
- A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses.
- Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.
- Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia.
- Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia.
- Encephalitozoon hellem infection after haploidentical allogeneic hematopoietic stem cell transplantation in children: a case report.
- Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation.
- Low risk of relapse in aplastic anemia patients after SARS-CoV-2 omicron infection: A prospective NICHE cohort.
- Mass cytometry analysis identifies T cell immune signature of aplastic anemia and predicts the response to cyclosporine.
- Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia.
- Haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia and non-hepatitis-associated aplastic anaemia: A propensity score-matched analysis.
- Phenotypic and genotypic correlation evaluation of 148 pediatric patients with Fanconi anemia in a Chinese rare disease cohort.
- Long-term outcomes of aplastic anemia with cytogenetic abnormalities at diagnosis.
- Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia.
- Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis-associated aplastic anemia.
- Association between human leukocyte antigen and immunosuppressive treatment outcomes in Chinese patients with aplastic anemia.
- Interleukin-10 promoter variability is associated with the susceptibility, severity, and clinical outcomes of aplasitc anemia in Han-Chinese population.
- Single-cell analysis highlights a population of Th17-polarized CD4+ naïve T cells showing IL6/JAK3/STAT3 activation in pediatric severe aplastic anemia.
- Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.
- Application of serum Raman spectroscopy in rapid and early discrimination of aplastic anemia and myelodysplastic syndrome.
- Impaired immunosuppressive effect of bone marrow mesenchymal stem cell-derived exosomes on T cells in aplastic anemia.
- Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases.
- First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years' experience.
- Leptin-mediated proinflammatory bone marrow environment in acquired aplastic anemia.
- The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: A single-center, retrospective study.
- Levamisole Suppresses CD4+ T-Cell Proliferation and Antigen-Presenting Cell Activation in Aplastic Anemia by Regulating the JAK/STAT and TLR Signaling Pathways.
- Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors.
- Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia.
- Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia.
- Short Stature in Patients with Diamond-Blackfan Anemia: A Cross-Sectional Study.
- Efficacy of anti-thymocyte globulin for platelet transfusion refractoriness in serious aplastic anemia patients.
- PNH Clones for Aplastic Anemia with Immunosuppressive Therapy: A Systematic Review and Meta-Analysis.
- Red blood cell lifespan is reduced in severe aplastic anemia and improves with response to immunosuppressive treatment.
- Time and residual hematopoiesis are crucial for PNH clones escape in hepatitis-associated aplastic anemia.
- Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine.
- Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia.
- Successful Treatment of a 19-Month-Old Boy with Hepatitis Associated Aplastic Anemia by Infusion of Umbilical Cord-Derived Mesenchymal Stromal Cells: A Case Report.
- Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia.
- Platelet/Lymphocyte ratio independently predicts the outcome of severe aplastic anemia patients treated with antithymocyte globulin.
- Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?-a systematic review and meta-analysis.
Chinese-language papers (not in the count)24
- [Advancements in CRISPR-Cas9 for Fanconi anemia].
- [Melatonin-Mediated Inhibitory Effect on Hyperimmune Status of Acquired Aplastic Anemia].
- [Clinical characteristics of aplastic anemia patients with abnormal autoantibodies and the impact of autoantibodies on immunosuppressive therapy response].
- [Evaluation of the clinical manifestations of COVID-19 in patients with aplastic anemia undergoing immunosuppressive therapy: a prospective cohort study (NICHE)].
- [Efficacy and safety of allogeneic hematopoietic stem cell transplantation in the treatment of 28 patients with hepatitis-related aplastic anemia].
- [Metagenomic next-generation sequencing of plasma for the identification of bloodstream infectious pathogens in severe aplastic anemia].
- [The effect of on-demand glucocorticoid strategy on the occurrence and outcome of p-ALG-associated serum sickness in aplastic anemia].
- [Clinical analysis of 76 patients with severe aplastic anemia treated with haploid hematopoietic stem cell transplantation].
- [T-large granular lymphocytic leukemia presenting as aplastic anemia: a report of five cases and literature review].
- [Prevalence and risk factors of obesity in children with Diamond-Blackfan anemia].
- Significance of paroxysmal nocturnal hemoglobinuria clone in immunosuppressive therapy for children with severe aplastic anemia.
- [Avatrombopag combined with standard immunosuppressive therapy in the treatment of severe aplastic anemia with hepatic impairment in six patients].
- [Hematologic responses to avatrombopag switch in TPO-RA refractory aplastic anemia].
- [Kinetics of immune activated T cells in aplastic anemia mouse model].
- [Pharmacokinetic study of anti-human T-cell porcine immunoglobulin combined with cyclosporine A immunosuppressive therapy in patients with severe aplastic anemia].
- [Reassessing the six months prognosis of patients with severe or very severe aplastic anemia without hematological responses at three months after immunosuppressive therapy].
- [Bone marrow failure with body deformities].
- Research advances on haploidentical hematopoietic stem cell transplantation in the treatment of severe aplastic anemia in children.
- [Clinical Characteristics and Prognosis Analysis of Pediatric Severe Aplastic Anemia].
- [Optimization of Mouse Model of Aplastic Anemia Induced by Pan T Lymphocytes Combined with Irradiation].
- [Relationship between Changes of Lymphocyte Subsets and Early Hematologic Response in Immunosuppressive Therapy of Severe Aplastic Anemia Patients].
- [Advances in bone marrow failure related ribosomopathies].
- [Syngeneic hematopoietic stem cell transplantation for aplastic anemia].
- [A real-world study of 176 cases with aplastic anemia treated in outpatient].
All its trials on ClinicalTrials.gov, any status35
- Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
- Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
- Reproductive and Mental Health of Patients With Aplastic Anemia
- Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
- The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
- Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
- Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
- Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
- National Longitudinal Cohort of Hematological Diseases
- CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
- Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia
- Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
- Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia
- Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia
- Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function
- Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly
- The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA
- A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency
- Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia
- Avatrombopag Combined With IST as First-line Treatment for SAA
- Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA
- Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia
- A Randomized, Controlled Clinical Study on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Combined With Standard Immunosuppressants in the Treatment of Children With Severe Aplastic Anemia
- A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
- Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived)
- Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
- Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia
- Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents
- Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
- Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia
- Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
- Extension Study of Hetrombopag in Severe Aplastic Anemia
- A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) Patient
Blood disorders
Beta thalassaemia
β 地中海贫血Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.
- Open trials led
- 0
- recruiting or about to
1 hospital in Tianjin for beta thalassaemia157 hospitals in China for beta thalassaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Recruitingβ-Thalassemia Treatment With KL003 Cell Injection
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Registry
- NCT06280378
Age 3 years to 35 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status8
- Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
- Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
- Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
- Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
- Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia
- Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
- β-Thalassemia Treatment With KL003 Cell Injection
- A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
Blood disorders
Haemophilia A
血友病 ALed 25 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 9.2%.
1 hospital in Tianjin for haemophilia A160 hospitals in China for haemophilia A
Open trials with this hospital 11
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSafety and Efficacy Study of NGGT003 in Hemophilia A Patients
- Phase
- Early phase 1
- Started
- 2024-01
- Registry
- NCT06238908
Age 18 years to Not stated; men only (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
- Phase
- Phase 4
- Started
- 2023-11
- Registry
- NCT05888870
Age 14 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of FVIII Gene Therapy for Hemophilia A
- Phase
- Early phase 1
- Started
- 2022-07
- Registry
- NCT05454774
Age 18 years to Not stated; men only (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingGene Therapy for Chinese Hemophilia A
- Phase
- N/A
- Started
- 2021-03
- Registry
- NCT04728841
Age 18 years to Not stated; men only (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingNational Longitudinal Cohort of Hematological Diseases
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04645199
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07416604
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Tianjin
- RecruitingSafety of KN057 Prophylaxis in Patients With Haemophilia A or B
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07545395
Age 12 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingTo Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06833983
Age 18 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou
- RecruitingEvaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- Phase
- Phase 2/Phase 3
- Started
- 2024-01
- Registry
- NCT06111638
Age 18 years to Not stated; men only (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi’an
- RecruitingA Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Phase
- Phase 3
- Started
- 2022-12
- Registry
- NCT05611801
Age 1 year to 17 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan
- RecruitingOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Phase
- Phase 3
- Started
- 2021-11
- Registry
- NCT05145127
Age 1 year to 74 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led25
- Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.
- The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.
- Nationwide Survey of Laboratory Practices for Factor VIII Inhibitor Detection in China.
- The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.
- Biomembrane-inspired lipid nanoparticles enhance CRISPR-Cas9 editing for hemophilia A.
- Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.
- Decoding the complexity of on-target integration: characterizing DNA insertions at the CRISPR-Cas9 targeted locus using nanopore sequencing.
- Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in China.
- Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia.
- Efficacy and safety of the B-domain-deleted TQG202 for on-demand treatment in moderate and severe haemophilia A patients: A multicentre, single-arm trial.
- Women and girls with haemophilia: A retrospective cohort study in China.
- Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.
- Anti-CD38 antibody for refractory acquired hemophilia A.
- Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors.
- Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.
- Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
- Health-related quality of life among adults with haemophilia in China: A comparison with age-matched general population.
- Haemophilia gene therapy-Update on new country initiatives.
- Demographics, clinical profile and treatment landscape of patients with haemophilia B in China.
- Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A.
- Total Knee Arthroplasty after Gene Therapy for Hemophilia B.
- Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices.
- Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up.
- Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.
- An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies.
Chinese-language papers (not in the count)5
- [How I treat acquired clotting factor deficiency].
- [Clinical efficacy and safety of Octocog alfa in Chinese patients with hemophilia A: One-year follow-up results from the Antihemophilic Factor Hemophilia A Outcome Database (AHEAD) study].
- [Keeping up with the trends and improving the hierarchical system for the diagnosis and treatment of hemophilia in China].
- [Recent advances in the replacement therapy for Hemophilia].
- [Advances in long-acting recombinant factor Ⅸ for the treatment of hemophilia B].
Earlier papers (2016–2020)19
- Growing success and ambitions of the Chinese edition of Haemophilia.
- Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China.
- Haemophilia care in China: Achievements in the past decade.
- Real-world analysis of haemophilia patients in China: A single centre's experience.
- Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China.
- Outcome of CARE: a 6-year national registry of acquired haemophilia A in China.
- Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse.
- Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
- [How I treat hemophilia with inhibitors].
- [HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy].
- [A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B].
- [Clinical application and optimization of HEAD-US quantitative ultrasound assessment scale for hemophilic arthropathy].
- Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.
- [Immune tolerance induction in a case of hemophilia B with inhibitor with prothrombin complex concentrate and rituximab].
- [Advances in Hemophilia A inhibitors].
- [Analysis of clinical efficacy of recombinant activated factor Ⅶ on bleeding in patients with hematologic disorders].
- [Retrospectively analysis of the difference of bleeding frequency and hemophilic arthropathy between hemophilia A and hemophilia B patients].
- Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing.
- [Study on risk factors and follow-up of 26 hemophilia A children with inhibitors].
All its trials on ClinicalTrials.gov, any status47
- Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
- ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
- A Study of FVIII Gene Therapy for Hemophilia A
- Gene Therapy for Chinese Hemophilia A
- National Longitudinal Cohort of Hematological Diseases
- A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A
- The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.
- Data Registry in Chinese Hemophilia A and B Patients
- Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
- SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
- To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- A Phase I of SS109 in Hemophilia A or and B With Inhibitors
- A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
- A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
- Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
- A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
- Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
- Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.
- A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
- Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
- A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Tianjin for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Fanconi anaemia
范可尼贫血Led 3 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 4.4%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Tianjin for Fanconi anaemia40 hospitals in China for Fanconi anaemia
No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia.
- Phenotypic and genotypic correlation evaluation of 148 pediatric patients with Fanconi anemia in a Chinese rare disease cohort.
- Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status1
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Tianjin for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Tianjin for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Gaucher disease
戈谢病Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Tianjin for Gaucher disease41 hospitals in China for Gaucher disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06818838
Age 18 years to 60 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Taiyuan, Tianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Tianjin for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
中国医学科学院血液病医院(血液学研究所)
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
天津
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Yunnan Blood Disease Hospital; Insitute of Hematology & Blood Disarses Hospital; Blood Disease Hospital; Blood Diseases Hospital; Hematology and Blood Diseases Hospital; Institute of Hematology & Blood Diseases Hospital; Institute of Hematology and Blood Diseases Hospital; 中国医学科学院血液病医院